Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?
Schulze
A
A
Division of Metabolic Diseases, University Children's Hospital, Heidelberg, Germany.
Mayatepek
E
E
Frank
S
S
Marescau
B
B
De Deyn
P P
PP
Bachert
P
P
D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D004827:Epilepsy / Q000139:chemically induced* / Q000188:drug therapy / Q000652:urine; D005260:Female; D006146:Guanidines / Q000652:urine*; D006801:Humans; D007223:Infant; D011422:Propionates / Q000652:urine*; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D006146:Guanidines; D011422:Propionates; C001317:gamma-guanidinobutyric acid; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin; C005775:guanidinopropionic acid